Immuneering Corp Class A

IMRX NASDAQ Santé & Biotech États-Unis US45254E1073
4.41 $

Immuneering Corp se focalise sur le développement de médicaments bioinformatiques pour traiter les maladies causées par des dysfonctionnements du signal cellulaire, notamment le cancer.

Performance & Momentum

6 Months 21.95 %
1 Year 72.27 %
3 Years 61.38 %
5 Years 74.93 %

Similar stocks to Immuneering Corp Class A

Anantys Community

Be the first to share your analysis on Immuneering Corp Class A.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases